Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
5.31
-0.27 (-4.84%)
Oct 10, 2025, 4:00 PM EDT - Market closed
Serina Therapeutics Revenue
Serina Therapeutics had revenue of $130.00K in the quarter ending June 30, 2025, with 154.90% growth. This brings the company's revenue in the last twelve months to $130.00K, down -95.90% year-over-year. In the year 2024, Serina Therapeutics had annual revenue of $56.00K, down -98.22%.
Revenue (ttm)
$130.00K
Revenue Growth
-95.90%
P/S Ratio
430.42
Revenue / Employee
$10,000
Employees
13
Market Cap
55.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.00K | -3.10M | -98.22% |
Dec 31, 2023 | 3.15M | 2.56M | 433.05% |
Dec 31, 2022 | 591.50K | 447.50K | 310.76% |
Dec 31, 2021 | 144.00K | -217.00K | -60.11% |
Dec 31, 2020 | 361.00K | -1.37M | -79.11% |
Dec 31, 2019 | 1.73M | 332.00K | 23.78% |
Dec 31, 2018 | 1.40M | -8.00K | -0.57% |
Dec 31, 2017 | 1.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SER News
- 3 days ago - Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors - GlobeNewsWire
- 5 days ago - Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease - GlobeNewsWire
- 4 weeks ago - Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease - GlobeNewsWire
- 4 weeks ago - Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 weeks ago - Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway - GlobeNewsWire
- 2 months ago - Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 2 months ago - Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD) - GlobeNewsWire
- 2 months ago - Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference - GlobeNewsWire